FCLYELAR

The most potent activity was exhibited by the synthesized peptide FCLYELAR, recording an IC50 value of 31.63 ± 0.15 μM.

In the case of the FCLYELAR peptide, Ki measured a constant 0.0248 mM as shown in Fig 6.

The F7 fraction provided the greatest ACE-inhibitory activity among those fractions tested, offering an IC50 value of 0.26 ± 0.02 μg/mL.

Those fractions whose molecular weights did not exceed 0.65 kDa provided the best ACE-inhibitory activity (IC50 0.093 ± 0.004 μg/mL).

For IC50 the experimental value was a little higher than the prediction at 7.14 ± 0.05 μg/mL.

Run 19 provided the lowest experimental value for ACE-inhibitory activity at 6.87 μg/mL.

Table 3 also shows the ACE-inhibitory activity, with results in the range of 6.87 to 12.55 μg/mL.

Table 5: 0.65–3 kDa fraction IC50 0.303 ± 0.025 μg/mL.

Table 5: 3–5 kDa fraction IC50 2.078 ± 0.424 μg/mL.

Table 5: 5–10 kDa fraction IC50 42.640 ± 3.358 μg/mL.

Table 5: >10 kDa fraction IC50 21.556 ± 0.891 μg/mL.

Table 5: Unfractionated hydrolysate IC50 7.140 ± 0.051 μg/mL.

Table 6: F2 fraction IC50 > 0.28 μg/mL.

Table 6: F3 fraction IC50 > 0.25 μg/mL.

Table 6: F4 fraction IC50 > 0.29 μg/mL.

Table 6: F5 fraction IC50 > 0.25 μg/mL.

Table 6: F6 fraction IC50 > 0.16 μg/mL.

Table 6: F8 fraction IC50 > 1.09 μg/mL.

Table 6: F9 fraction IC50 1.60 ± 0.15 μg/mL.

Table 6: F10 fraction IC50 1.12 ± 0.05 μg/mL.

Table 6: F11 fraction IC50 0.34 ± 0.01 μg/mL.

Table 6: F12 fraction IC50 0.88 ± 0.01 μg/mL.

Table 6: F13 fraction IC50 0.97 ± 0.02 μg/mL.

Table 6: F14 fraction IC50 1.22 ± 0.11 μg/mL.

Table 6: F15 fraction IC50 1.70 ± 0.34 μg/mL.

Table 6: F16 fraction IC50 1.22 ± 0.20 μg/mL.

Table 6: F1 fraction IC50 N.D.